Search Results
242 results
Your search is now limited to «AbbVie» expert search.
FiercePharmaManufacturing 03/22/2019 11:13
Boehringer Ingelheim and AbbVie’s Skyrizi captures the No. 5 position in Cortellis’ Drugs to Watch ranking.
More from FiercePharmaManufacturing:
NASDAQ 03/21/2019 22:07
While Lilly's shares have taken flight due to the company's rising sales and streamlined business structure , AbbVie's stock has nosedived in response to the drugmaker's inability to diversify its revenue stream in a significant way.
More from NASDAQ:
Seeking Alpha 03/21/2019 15:07
My point here is that despite taking AbbVie's coming drug pipeline as just that - the coming drug pipeline, there is strong promise in the drugs that AbbVie expects to replace Humira's sales.
More from Seeking Alpha:
PR Newswire 03/21/2019 14:59
At AbbVie, we understand that education is essential to help young people succeed inside and outside of the classroom," said Laura Schumacher , vice chairman, external affairs and chief legal officer, AbbVie.
More from PR Newswire:
BioPharma Dive 03/20/2019 12:15
In a statement, AbbVie said it is working with the FDA and other regulatory authorities to determine next steps for investigational clinical trials of the drug in multiple myeloma.
More from BioPharma Dive:
FDLI SmartBrief 03/20/2019 09:51
The FDA has issued a partial clinical hold on trials of AbbVie's Venclexta, or venetoclax, for multiple myeloma after data indicated a higher mortality rate in a late-stage study's Venclexta arm.
More from FDLI SmartBrief:
pharmaphorum 03/20/2019 07:18
AbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a higher proportion of deaths was observed in patients receiving it than in a trial’s control arm.
More from pharmaphorum:
(MENAFN - iCrowdNewsWire) iCrowdNewswire - Mar 20, 2019 "Global Hepatitis Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry ...
More from Middle East North Africa Financial Network (MENAFN): 03/19/2019 20:19
AbbVie hit with antitrust lawsuit over Humira 'patent thicket'.
More from
PMLiVE 03/19/2019 12:42
AbbVie's Michael Severino “We are committed to patient safety and are thoroughly analysing the results observed in the BELLINI trial,” said Michael Severino, AbbVie’s vice chairman and president.
More from PMLiVE:
Benzinga 03/19/2019 10:00
The panel also focused on AbbVie's use of a patent thicket as a barrier to competition from more affordable treatments.
More from Benzinga:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications